Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the most common form of dementia in the elderly. Concurrent with an aging population, the incidence of AD has been rising steadily and become a global threat to public health . Unfortunately, there are currently no effective interventions that can cure AD or slow its progression, and recently finished clinical trials targeting brain amyloid-β (Aβ) accumulation have not succeeded in improving cognitive impairments in AD patients . Thus, it is necessary and urgent to identify alternative disease-modifying strategies to alleviate AD pathophysiology. In this perspective article, we focus on glucagon-like peptide-1 (GLP-1), specifically its natural cleavage product GLP-1 (9-36), as a potential therapeutic approach for AD.
Biology of GLP-1
GLP-1 is an incretin hormone released from the L-cells of the distal ileum in response to nutrient ingestion. This proglucagon protein is a prohormone which gives rise to several...
This insight was supported by the National Institutes of Health, USA (K99/R00 AG044469, R01 AG055581, and R01 AG056622), and the BrightFocus Foundation (A2017457S).
Conflict of interest
The authors declare no conflict of interest.
- 1.Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 2011, 3: 77sr71.Google Scholar
- 7.Holscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases. Acta Physiol Sin 2014, 66: 497–510.Google Scholar